# A Study Evaluating the Efficacy and Safety of Neihulizumab vs "Conventional Treatment" to Treat Sr-aGvHD

> **NCT02694770** · PHASE2 · WITHDRAWN · sponsor: **AbGenomics B.V Taiwan Branch**

## Conditions studied

- Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation

## Interventions

- **BIOLOGICAL:** Neihulizumab Treatment
- **BIOLOGICAL:** Conventional Treatment

## Key facts

- **NCT ID:** NCT02694770
- **Lead sponsor:** AbGenomics B.V Taiwan Branch
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-07
- **Primary completion:** 2017-09
- **Final completion:** 2018-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** corporate decision
- **Last updated:** 2016-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02694770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02694770, "A Study Evaluating the Efficacy and Safety of Neihulizumab vs "Conventional Treatment" to Treat Sr-aGvHD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02694770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*